Brief: Inozyme Pharma Expects To Initiate Phase 1/2 Trials Of Inz-701 For ENPP1 Deficiency In First Half Of Year

Inozyme Pharma

25/03/2021 10:03

March 25 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA REPORTS FULL YEAR 2020 FINANCIAL RESULTS
AND
PROVIDES BUSINESS HIGHLIGHTS
    * INOZYME PHARMA INC - CASH, CASH EQUIVALENTS, AND
INVESTMENTS
EXPECTED TO ENABLE CONTINUED OPERATIONS INTO SECOND HALF OF 2022
    * INOZYME PHARMA INC - EXPECT TO INITIATE PHASE 1/2 TRIALS
OF
INZ-701 FOR ENPP1 DEFICIENCY IN FIRST HALF OF YEAR AND ABCC6
DEFICIENCY BY MID-2021

Source text for Eikon:  ID:nGNX5kNH5k 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))